Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement

Core Viewpoint - Aptose Biosciences Inc. shareholders are recommended to vote "FOR" the proposed arrangement with Hanmi Pharmaceutical Co. Ltd. to acquire all outstanding common shares not currently owned by Hanmi or its affiliates [1][8] Group 1: Arrangement and Continuance - Glass Lewis, an independent proxy advisory firm, has recommended that shareholders approve the arrangement with Hanmi [1] - The company is transitioning from being governed under the Canada Business Corporations Act to the Business Corporations Act (Alberta) [2] - The completion of the transaction is subject to customary closing conditions, including court approval and approval from the TSX [8] Group 2: Meeting Details - A special meeting of shareholders has been reconvened for March 31, 2026, at 11:00 a.m. (EST) to seek approval for the arrangement and continuance [4] - The meeting will be held virtually via live audio webcast [4] - Shareholders are encouraged to submit their proxies ahead of the voting deadline on March 27, 2026, at 11:00 a.m. (EST) [3][7] Group 3: Proxy Statement and Voting Assistance - Aptose has filed a definitive proxy statement with the SEC for the reconvened meeting, which has been mailed to all shareholders [5] - Shareholders who have questions or need voting assistance can contact Morrow Sodali (Canada) Ltd. [10]